Literature DB >> 14560791

CD54 and CD62L expression by lymphoid cells in acute lymphoblastic leukaemia in children.

F M Hafez1, H Hassab, Z Morad, E A M Farag.   

Abstract

Altered expression or function of adhesion molecules on leukaemic blasts may contribute to the evolution and biological behaviour of acute leukaemia. This work studies the expression of CD54 and CD62L by lymphoid cells and the serum level of the shed form of L-selectin (sL-selectin) in children with acute lymphoblastic leukaemia (ALL) at initial diagnosis and after first remission, and their relationship to disease activity and subtype. The study is conducted on 20 children (age range 2-10 years) newly diagnosed with ALL and admitted to Alexandria University Children's Hospital. Ten apparently healthy children of matched age and sex serve as a control group. Expression of CD54 and CD62L on mononuclear cells is detected by monoclonal antibodies using flow cytometry. Serum sL-selectin is measured by enzyme-linked immunosorbent assay (ELISA). B-cell ALL was the most common subtype (45%), followed by T-ALL (35%) and C-ALL (20%). CD54 and CD62L mean cellular expression, as well as serum sL-selectin level, were significantly higher at diagnosis than both after remission and in the control group. Univariate analysis showed that the presence of mediastinal mass, high leucocyte count, central nervous system involvement and low CD54 were significant predictors of mortality in children with ALL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14560791     DOI: 10.1080/09674845.2003.11783692

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  1 in total

1.  iTRAQ-based quantitative protein expression profiling of biomarkers in childhood B-cell and T-cell acute lymphoblastic leukemia.

Authors:  Runhong Yu; Jingyu Zhang; Yuzhu Zang; Li Zeng; Wenli Zuo; Yanliang Bai; Yanhui Liu; Kai Sun; Yufeng Liu
Journal:  Cancer Manag Res       Date:  2019-07-25       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.